Thrombolytic treatment of acute ischemic stroke

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Intravenous recombinant tissue-type plasminogen activator is approved by the US Food and Drug Administration for treating acute ischemic stroke within 3 hours of onset of symptoms. Initiation of thrombolysis within 90 minutes of onset of symptoms is a treatment goal supported by current studies. Postmarketing data suggest that the risk of intracranial hemorrhage may be unacceptably high when recombinant tissue-type plasminogen activator is given to patients who would not have been eligible for enrollment in the pivotal phase 3 clinical trials. Further studies of local intra-arterial thrombolysis and improved selection of patients with advanced brain imaging are expected in the future, but the emphasis at present should be on rapid identification, evaluation, and treatment of appropriate patients with intravenous therapy.

Original languageEnglish (US)
Pages (from-to)542-551
Number of pages10
JournalMayo Clinic Proceedings
Volume77
Issue number6
StatePublished - 2002

Fingerprint

Stroke
Tissue Plasminogen Activator
Phase III Clinical Trials
Intracranial Hemorrhages
United States Food and Drug Administration
Neuroimaging
Patient Selection
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thrombolytic treatment of acute ischemic stroke. / Meschia, James F; Miller, David A.; Brott, Thomas G.

In: Mayo Clinic Proceedings, Vol. 77, No. 6, 2002, p. 542-551.

Research output: Contribution to journalArticle

@article{b1238fdf13314bc39e5e5ae75067b214,
title = "Thrombolytic treatment of acute ischemic stroke",
abstract = "Intravenous recombinant tissue-type plasminogen activator is approved by the US Food and Drug Administration for treating acute ischemic stroke within 3 hours of onset of symptoms. Initiation of thrombolysis within 90 minutes of onset of symptoms is a treatment goal supported by current studies. Postmarketing data suggest that the risk of intracranial hemorrhage may be unacceptably high when recombinant tissue-type plasminogen activator is given to patients who would not have been eligible for enrollment in the pivotal phase 3 clinical trials. Further studies of local intra-arterial thrombolysis and improved selection of patients with advanced brain imaging are expected in the future, but the emphasis at present should be on rapid identification, evaluation, and treatment of appropriate patients with intravenous therapy.",
author = "Meschia, {James F} and Miller, {David A.} and Brott, {Thomas G}",
year = "2002",
language = "English (US)",
volume = "77",
pages = "542--551",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Thrombolytic treatment of acute ischemic stroke

AU - Meschia, James F

AU - Miller, David A.

AU - Brott, Thomas G

PY - 2002

Y1 - 2002

N2 - Intravenous recombinant tissue-type plasminogen activator is approved by the US Food and Drug Administration for treating acute ischemic stroke within 3 hours of onset of symptoms. Initiation of thrombolysis within 90 minutes of onset of symptoms is a treatment goal supported by current studies. Postmarketing data suggest that the risk of intracranial hemorrhage may be unacceptably high when recombinant tissue-type plasminogen activator is given to patients who would not have been eligible for enrollment in the pivotal phase 3 clinical trials. Further studies of local intra-arterial thrombolysis and improved selection of patients with advanced brain imaging are expected in the future, but the emphasis at present should be on rapid identification, evaluation, and treatment of appropriate patients with intravenous therapy.

AB - Intravenous recombinant tissue-type plasminogen activator is approved by the US Food and Drug Administration for treating acute ischemic stroke within 3 hours of onset of symptoms. Initiation of thrombolysis within 90 minutes of onset of symptoms is a treatment goal supported by current studies. Postmarketing data suggest that the risk of intracranial hemorrhage may be unacceptably high when recombinant tissue-type plasminogen activator is given to patients who would not have been eligible for enrollment in the pivotal phase 3 clinical trials. Further studies of local intra-arterial thrombolysis and improved selection of patients with advanced brain imaging are expected in the future, but the emphasis at present should be on rapid identification, evaluation, and treatment of appropriate patients with intravenous therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036264097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036264097&partnerID=8YFLogxK

M3 - Article

C2 - 12059124

AN - SCOPUS:0036264097

VL - 77

SP - 542

EP - 551

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -